



# Biotech Daily

Thursday December 2, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: RESONANCE UP 5%;  
- COMPUMEDICS, UNIVERSAL BIOSENSORS DOWN 4.4%**
- \* **ONCOLOGY ONE, WEHI, CURTIN UNI WORK ON BREAST CANCER**
- \* **PATRYS RIGHTS RAISE \$5.33m, TOTAL \$7.83m**
- \* **IMAGION OPTIONS RAISE \$4.8m**
- \* **OSTEOPORE: HONG KONG APPROVES BONE SCAFFOLD**
- \* **MEMPHASYS COMPLETES SAMSON SPERM DATA COLLECTION**
- \* **IMMUTEP: IMP321 'SAFE' FOR 5 TRIPLE COMBO TUMOR PATIENTS**
- \* **AMPLIA: VICTORIA \$2.1m R&D TAX INCENTIVE LOAN**
- \* **CLARITY: CARDINAL TO MANUFACTURE COPPER PRODUCTS FOR US TRIAL**
- \* **HERAMED: HERACARE PAID PROGRAM ENROLS 80 PATIENTS**
- \* **ZELIRA: LEVIN MARIJUANA ZTL-106 PAIN TRIAL APPROVED**
- \* **CRESO: HALUCENEX CANADA PSYCHEDELICS LICENCE 'UPGRADE'**
- \* **MONTGOMERY TAKES 5% OF AVITA**
- \* **ELIXXER REDUCES TO 10.5% OF LITTLE GREEN**
- \* **HEXIMA: PROF ANDERSON OFF-BOARD, DR SACCO CDO, PROF LIPNER ADVISER**

## MARKET REPORT

The Australian stock market fell 0.15 percent on Thursday December 2, 2021, with the ASX200 down 10.7 points to 7,225.2 points. Ten of the Biotech Daily Top 40 stocks were up, 19 fell, 10 traded unchanged and one was untraded.

Resonance was the best, up 0.5 cents or five percent to 10.5 cents, with 170,541 shares traded. Cynata climbed three percent; Clinuvel, Imugene, LBT and Patrys rose two percent or more; Medical Developments and Telix were up more than one percent; with Cochlear, Kazia and Nanosonics up by less than one percent.

Compumedics and Universal Biosensors led the falls, both down 4.4 percent to 32.5 cents and 87 cents, respectively, with 16,357 shares and 190,751 shares traded, respectively. Alterity fell four percent; Genetic Signatures, Opthea, Paradigm, Polynovo, Pro Medicus and Starpharma lost more than three percent; Antisense, Avita, Impedimed, Mesoblast, Optiscan and Proteomics shed more than two percent; CSL, Immunetep, Neuren and Volpara were down more than one percent; with Osprey and Resmed down by less than one percent.

## ONCOLOGY ONE PTY LTD

### THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Oncology One says it will work with the Walter and Eliza Hall Institute and Perth's Curtin University on small molecule drugs for solid tumors, starting with breast cancer.

Melbourne's Oncology One said the project would identify small molecule compounds that inhibited a novel undisclosed target within the ubiquitin system in breast cancer that assisted tumor growth, and then refine selected compounds for clinical trials.

The company said that the project began in the research laboratories the Walter and Eliza Hall's Prof David Komander and Curtin University's Prof Pieter Eichhorn.

Oncology One said the objective was to develop a new therapeutic for treating metastatic oestrogen receptor positive (ER+) breast cancers that had escaped current treatments.

The company said that the new therapeutic had "the potential to address unmet clinical needs in other cancers such as colorectal and brain" as the ubiquitin system offered "many opportunities for innovative cancer treatments".

Oncology One scientific advisory board chair Dr Ian Street said the project was "an important next step for Oncology One in building a pipeline of drug discovery programs that are highly differentiated and address unmet clinical needs".

In August, Oncology One said it had partnered with Sydney's Children's Cancer Institute to develop small molecule drugs to treat of paediatric solid tumors, including neuroblastoma (BD: Aug 26, 2021)

Dr Street said there had been "great progress in early breast cancer detection, and this has had a dramatic effect on reducing mortality". "However, if early disease is missed and the cancer metastasizes, then unfortunately prognosis is poor."

The company said breast cancer was the most prevalent cancer in women, accounting for more than two million cases and more than 600,000 deaths a year, with resistance to existing therapies "a major challenge in the treatment of many people with breast cancer, and new treatment modalities are urgently required to improve patient outcomes".

Prof Eichorn said that while breast cancer survival rates had improved "there are millions of patients who don't respond to current treatments".

Oncology One is a private company.

## PATRY'S

Patry's says it had applications for \$4,952,173 in its under-written, one-for-12, rights issue at 3.5 cents a share; taking the total raised to \$7.83 million 3452,173.

Last month, Patry's said it raised \$2.5 million in a placement at 3.5 cents a share and expected to raise up to \$5.3 million through the rights offer (BD: Nov 1, 2021).

Today, the company said it had to scale back top-up applications and the shortfall of 24,314,474 shares worth \$851,007 would be allocated to Lazarus Corporate Finance.

Patry's was up 0.1 cents or 2.7 percent to 3.8 cents with 3.5 million shares traded.

## IMAGION BIOSYSTEMS

Imagion says it has received \$4.8 million from the exercise of all 96,706,395 listed options, exercisable at five cents each by November 26, 2021.

Last week, Imagion said Mercer Street Global Opportunity Fund had underwritten 16,161,610 options (BD: Nov 25, 2021)

Today, the company said that 94,708,863 options had been exercised by option holders with the balance of 1,997,532 exercised by Mercer Street.

Imagion fell 0.2 cents or 2.4 percent to 8.2 cents with 10.9 million shares traded.

## OSTEOPORE

Osteopore says Hong Kong's Medical Device Control System has registered its bio-resorbable bone scaffold.

Osteopore said that registration in Hong Kong was voluntary but "registered medical devices are typically given preference for use".

The company said that a pilot program launched late last year allowed for "expedited partial access to the lucrative Chinese market, a process that could take at least a few years".

Osteopore said that the program provided access to the Greater Bay Area, comprising Hong Kong, Macao, and the nine municipalities of Guangzhou in the Guangdong Province, about 11 percent of China's economy.

Osteopore was up half a cent or 2.2 percent to 23.5 cents.

## MEMPHASYS

Memphasys says that data on 240 mare inseminations has been collected for its Samson stallion sperm quality test, with results expected by April 2022.

Memphasys said the data was collected from two equine studs during the horse breeding season in October and November 2021 with data on the mare and the pregnancy outcome being collated.

The company said the University of Newcastle was analyzing the field trial data combined with pregnancy outcome and previous individual mare and stallion breeding statistics to determine the accuracy of the device in predicting mare pregnancy.

Memphasys said that if a positive correlation was achieved, a Samson pregnancy prediction algorithm for the specific stallion and mare pairing would be developed and a final commercial device would be built for use in the next breeding season.

Memphasys fell 0.4 cents or 4.1 percent to 9.3 cents.

## IMMUTEP

Immutep says its triple combination trial of IMP321 or eftilagimod alpha with chemotherapy and PD-1 drug for solid tumors is safe in the first five patients

In August, Immutep said it dosed the first of up to 20 patients in its first-in-human, phase I, 'Insight-003' trial of IMP321 for solid tumors (BD: Aug 5, 2021).

Today, the company said the trial would evaluate the combination of eftilagimod alpha with carboplatin and an anti-programmed cell death protein 1 (PD-1) therapy.

Immutep said no additional safety signals had been observed, with results expected in 2022.

Immutep fell half a cent or 1.05 percent to 47 cents with three million shares traded.

## AMPLIA THERAPEUTICS

Amplia says it has been granted a \$2.1 million loan from the Victorian Government's Research and Development Cash Flow Loan Initiative.

Amplia said the loan related to the research and development expenditure for the year to March 31, 2022 and was in addition to the incentive for the year to March 31, 2021.

The company said the loan facility would be awarded in two tranches with \$1.3 million in December 2021 and \$800,000 in the quarter ending March 31, 2022.

Amplia was unchanged at 17.5 cents.

## CLARITY PHARMACEUTICALS

Clarity says Dublin, Ohio's Cardinal Health will manufacture its copper-based radio-pharmaceuticals for diagnostics and therapy for US clinical trials.

Clarity said that Cardinal would manufacture ready to use copper-64 for targeted diagnosis of cancer and copper-67 for targeted treatment at the Indianapolis, Indiana Center for Theranostics Advancement.

In September, Clarity said the Springfield, New Jersey-based Evergreen Theragnostics Inc would manufacture the copper isotope products for its US trials (BD: Sep 30, 2021). Clarity was unchanged at 90 cents.

## HERAMED

Heramed says 80 of the hoped-for 100 expectant mothers have been enrolled in a paid pilot program of its foetal heart monitor at Perth's Joondalup Health Campus.

In August, Heramed said it begun a \$50 per user per month paid pilot program of its Heracare foetal heart monitor involving 100 expectant mothers (BD: Aug 13, 2021).

Today, the company said that the 80 expectant mothers were receiving ongoing remote antenatal care services with interim results showing up to 94 percent of patients saying they felt "well supported by their care team" while using the product and would "highly recommend a friend to use Heracare".

Heramed was unchanged at 28 cents.

## ZELIRA THERAPEUTICS

Zelira says Melbourne's Levin Health has been approved for a 114-patient, phase II trial of its marijuana-derived ZTL-106 for sports-related chronic pain.

In June, Zelira said it had licenced ZTL-106 to related-party Levin Health for a clinical trial in chronic pain for retired athletes (BD: Jun 3, 2021).

The company said it also had a project management deal with Levin Health, which would pay Zelira an undisclosed fee to manage the trial at Melbourne's La Trobe University's Sport and Exercise Medicine Research Centre.

Today, Zelira said that the randomized, double blind, placebo-controlled trial would investigate the use of ZTL-106 as an effective medicinal cannabis drug in treating people with chronic pain, specifically following Musculo-skeletal injury.

Zelira said that the trial was expected to begin in April 2022 with Prof Peter Brukner as the principal investigator.

Zelira was up 0.2 cents or 5.9 percent to 3.6 cents.

## CRESO PHARMA

Creso says Health Canada has upgraded subsidiary Halucenex Life Sciences' controlled drugs and substances dealer's licence to include production and packaging.

In August, Creso said Health Canada has approved a controlled drugs and substances dealer's licence for Halucenex (BD: Aug 16, 2021).

Today, the company said Halucenex now possessed the "most extensive license in regards to Controlled Drugs and Substances that can be awarded by Health Canada, which is anticipated to be a major competitive advantage, with all five possible licence categories now granted".

Creso was up 0.4 cents or 4.2 percent to 10 cents with 7.6 million shares traded.

## AVITA MEDICAL

Sydney's Montgomery Investment Management says it has become a substantial shareholder in Avita medical with 6,147,402 shares or 5.03 percent.

Montgomery said it bought shares between August 12 and November 29, 2021 with the single largest purchase 247,777 shares for \$1,229,158 or \$4.96 a share.

Avita fell eight cents or 2.1 percent to \$3.73 with 372,345 shares traded.

## LITTLE GREEN PHARMA

Montreal's Elixer Limited says it has reduced its shareholding and has been diluted in Little Green Pharma from 27,410,781 shares (11.8%) to 24,710,796 shares (10.5%)

Elixer said between July and September 2021, it sold 2,699,985 shares for \$1,901,126 or 70.4 cents a share.

In June, Little Green said it had commitments to raise \$27.2 million in a placement at 60 cents a share to buy a Denmark marijuana production facility (BD: Jun 22, 2021).

Little Green fell half a cent or 0.8 percent to 64 cents.

## HEXIMA

Hexima says Prof Marilyn Anderson has resigned as a director, with Dr Nancy Sacco appointed chief development officer and Prof Shari Lipner adviser.

Hexima said Prof Anderson was a founder of the company and would continue as its chief scientific officer.

The company said that the San Francisco-based Dr Sacco was previously the head of clinical development at Xentria and Anaptysbio and had worked for Revance Therapeutics and Avexis.

According to her LinkedIn page, Dr Sacco held a Bachelor of Science from Connecticut's Fairfield University and a Doctor of Philosophy from the Morgantown-based West Virginia University.

The company said that Prof Lipner had been appointment to its scientific advisory board and was a professor of clinical dermatology at New York's Weill Cornell Medical Center. The company said Prof Lipner had authored more than "250 peer-reviewed publications, numerous book chapters, lectures nationally and internationally".

Hexima said Prof Lipner held a Bachelor of Arts from Dartmouth College in Hanover, New Hampshire, with a Doctor of Medicine and Doctor of Philosophy from New York's Albert Einstein College of Medicine.

Hexima was up 1.5 cents or 4.55 percent to 34.5 cents.